Amiford
Amitriptyline 10mg
Amiford
Amitriptyline 25mg
BENEFITS
- A third-generation antipsychotic with a dopamine receptor-binding profile distinct from other second-generation antipsychotics
- Acts as partial agonist at dopamine D2 and 5-hydroxytryptamine (5-HT)1A receptors
- Stabilizes the dopamine receptor leading to improvement in symptoms
- Effective at attenuating negative and cognitive symptoms, in addition to positive symptoms, of schizophrenia
- Ensures better side effect profile
- Exhibits lower EPS liability than FGAS (e.g., haloperidol), lower weight gain and metabolic liabilities than SGAS (e.g., clozapine), and does not cause hyperprolactinemia
INDICATES IN
- Schizophrenia in adults and adolescents (13-17 years)
- Bipolar I disorder (manic and mixed episodes) in adults and pediatric patients (10-17 years)
- Major depressive disorder in adults, as an adjunctive therapy
- Major depressive disorder in adults, as an adjunctive therapy Irritability associated with autism spectrum disorder in pediatric patients (6-17 years)
- Vocal and motor tics associated with Tourette’s syndrome in pediatric patients (6-18 years)
CONTACT US
- Email: hello@email.com
- Phone/WhatsApp: +91 1234567890
- Website: www.website.com
